Karmanos Cancer Institute Rolls Out Revolutionary Treatment for Advanced Liver Cancer
In a groundbreaking development for cancer treatment, the Barbara Ann Karmanos Cancer Institute has announced the launch of the TheraBionic P1 device, specifically designed for the treatment of advanced hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. Uniquely, Karmanos is the first institution worldwide to prescribe this innovative, FDA-approved device, which allows patients to undergo treatment in the comfort of their homes.
The TheraBionic P1 is a portable, handheld device that operates using low levels of radiofrequency electromagnetic fields modulated to target the frequencies specific to liver cancer cells. Patients utilize the device by placing the spoon-shaped antenna on their tongues for three one-hour sessions each day. This method enables continuous delivery of therapeutic radiofrequency signals throughout the body, effectively stalling tumor growth while sparing healthy tissue from harm.
This device gained FDA approval in September 2023 for patients aged 18 and older who have exhausted first- and second-line treatment options for their advanced liver cancer. Dr. Boris Pasche, president and CEO of Karmanos and co-inventor of the TheraBionic P1, expressed the profound impact it could have on those suffering from incurable cancer. "This new treatment offers additional hope, extended life, and minimal side effects to patients," he stated.
Prior to the introduction of the TheraBionic P1, treatment options for advanced HCC patients with severely compromised liver function were limited. With average survival rates hovering between six to twenty months, the medical community has long sought innovative solutions. Research spanning over two decades has indicated that using the device can lead to tumor shrinkage, hinder the emergence of new cancer cells, and potentially enhance the overall survival rate of patients.
Patients have reported favorable outcomes with minimal side effects typically associated with conventional cancer treatments, such as loss of appetite and gastrointestinal distress. One poignant case is that of Robert Perrier, who was diagnosed with liver cancer in 2011. After undergoing various treatments, including surgery, he began using the P1 device in conjunction with oral chemotherapy. After two years, he ceased oral chemotherapy due to its side effects and relied solely on the TheraBionic P1 for nearly six additional years before passing away in 2017. His wife credits the device with significantly prolonging his life, remarking, "The TheraBionic device has provided my husband several additional years of life."
Dr. Anthony Shields, a medical oncologist at Karmanos, reflected on the device’s introduction with optimism, acknowledging its potential to give more time to patients and their families. The Karmanos Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team (MDT) is dedicated to creating personalized treatment plans that incorporate therapies like the TheraBionic P1, ensuring patients receive holistic care tailored for their unique needs.
Those interested in learning more about the TheraBionic device or scheduling a consultation may visit karmanos.org/therabionic or contact the Karmanos Cancer Institute directly. With this new addition to their array of treatment options, Karmanos is enhancing its commitment to fighting liver cancer, which according to the American Cancer Society, has seen a dramatic increase in incidence and mortality rates in recent years. As a comprehensive cancer center recognized for excellence in research and patient care, Karmanos continues to lead the way in advancing cancer treatment methods.
In summary, the launch of the TheraBionic P1 device signifies a major advancement in the quest to treat advanced liver cancer effectively. By merging innovative medical technology with compassionate care, Karmanos Cancer Institute strives to offer patients renewed hope and more options in their battle against cancer.
The TheraBionic P1 is a portable, handheld device that operates using low levels of radiofrequency electromagnetic fields modulated to target the frequencies specific to liver cancer cells. Patients utilize the device by placing the spoon-shaped antenna on their tongues for three one-hour sessions each day. This method enables continuous delivery of therapeutic radiofrequency signals throughout the body, effectively stalling tumor growth while sparing healthy tissue from harm.
This device gained FDA approval in September 2023 for patients aged 18 and older who have exhausted first- and second-line treatment options for their advanced liver cancer. Dr. Boris Pasche, president and CEO of Karmanos and co-inventor of the TheraBionic P1, expressed the profound impact it could have on those suffering from incurable cancer. "This new treatment offers additional hope, extended life, and minimal side effects to patients," he stated.
Prior to the introduction of the TheraBionic P1, treatment options for advanced HCC patients with severely compromised liver function were limited. With average survival rates hovering between six to twenty months, the medical community has long sought innovative solutions. Research spanning over two decades has indicated that using the device can lead to tumor shrinkage, hinder the emergence of new cancer cells, and potentially enhance the overall survival rate of patients.
Patients have reported favorable outcomes with minimal side effects typically associated with conventional cancer treatments, such as loss of appetite and gastrointestinal distress. One poignant case is that of Robert Perrier, who was diagnosed with liver cancer in 2011. After undergoing various treatments, including surgery, he began using the P1 device in conjunction with oral chemotherapy. After two years, he ceased oral chemotherapy due to its side effects and relied solely on the TheraBionic P1 for nearly six additional years before passing away in 2017. His wife credits the device with significantly prolonging his life, remarking, "The TheraBionic device has provided my husband several additional years of life."
Dr. Anthony Shields, a medical oncologist at Karmanos, reflected on the device’s introduction with optimism, acknowledging its potential to give more time to patients and their families. The Karmanos Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team (MDT) is dedicated to creating personalized treatment plans that incorporate therapies like the TheraBionic P1, ensuring patients receive holistic care tailored for their unique needs.
Those interested in learning more about the TheraBionic device or scheduling a consultation may visit karmanos.org/therabionic or contact the Karmanos Cancer Institute directly. With this new addition to their array of treatment options, Karmanos is enhancing its commitment to fighting liver cancer, which according to the American Cancer Society, has seen a dramatic increase in incidence and mortality rates in recent years. As a comprehensive cancer center recognized for excellence in research and patient care, Karmanos continues to lead the way in advancing cancer treatment methods.
In summary, the launch of the TheraBionic P1 device signifies a major advancement in the quest to treat advanced liver cancer effectively. By merging innovative medical technology with compassionate care, Karmanos Cancer Institute strives to offer patients renewed hope and more options in their battle against cancer.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.